ARID1A mutations are frequently detected in patients with endometrial cancer, and cell line assays have indicated increased tumorigenicity when ARID1A mutations are combined with other genomic abnormalities [46, 47]. The gene discussed is ARID1A; the disease is endometrial cancer.